Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases
The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223 ALM223 has the potential to rebalance...




















